Caselli Richard J, Yaari Roy
Department of Neurology, Mayo Clinic and Arizona Alzheimer's Disease Consortium, Scottsdale, Arizona 85259, USA.
Am J Alzheimers Dis Other Demen. 2007;22(6):489-98. doi: 10.1177/1533317507306654.
There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.
目前尚无美国食品药品监督管理局（FDA）批准用于额颞叶痴呆及其相关疾病药物治疗的药物，因此所有治疗建议均为超说明书用药，且借鉴了阿尔茨海默病、精神疾病及相关内科疾病的治疗经验。药物治疗需考虑的六个方面包括预防（一级和二级预防）、智力衰退、行为障碍（如抑郁、焦虑和精神病）、睡眠障碍、常见伴发疾病（包括运动神经元病）以及病情突然恶化。除药物治疗外，临床医生面临的重要生活方式问题还包括停止驾驶、妥善保管家中的任何武器、辅助生活以及照顾者倦怠。
